In this light, the recent case report by Kharel et al. [14] demonstrating the use of neoadjuvant chemotherapy in combination with a T-cell checkpoint inhibitor (pembrolizumab, a PD-1 inhibitor) to treat a TN IBC patient offers a bright light at the end of the dark tunnel faced by TN IBC patients. The gene discussed is PDCD1; the disease is inflammatory breast carcinoma.